Skin and soft tissue infections in biological therapy for psoriasis—A case report and systematic review of the literature

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

(2019) Erica D. Dommasch et al.   JAMA Dermatology

Real world data from the use of secukinumab in the treatment of moderate‐to‐severe psoriasis, including scalp and palmoplantar psoriasis: A 104‐week clinical study

(2019) Natalia Rompoti et al.   Dermatologic Therapy

Female patients are less satisfied with biological treatment for psoriasis and experience more side‐effects than male patients: results from the prospective BioCAPTURE registry

(2019) L.S. van der Schoot et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

(2018) J Reek et al.   ACTA DERMATO-VENEREOLOGICA

Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses

(2018) Stefanos Bonovas et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment

(2018) Alexander Nast et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2018) Zenas Z.N. Yiu et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2018) Z.Z.N. Yiu et al.   BRITISH JOURNAL OF DERMATOLOGY

Risk of Serious Infection among Patients Receiving Biologics for Chronic Inflammatory Diseases: Usefulness of Administrative Data

(2018) Luca Quartuccio et al.   Journal of Advanced Research

Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study

(2017) Nan-Lin Wu et al.   JOURNAL OF DERMATOLOGY

Serious infections among a large cohort of subjects with systemically treated psoriasis

(2017) Allison S. Dobry et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

(2017) Bruce Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries

(2017) Ignacio Garcia-Doval et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

(2016) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Bacterial Skin and Soft Tissue Infections in Adults: A Review of Their Epidemiology, Pathogenesis, Diagnosis, Treatment and Site Of Care

(2016) Vincent Ki et al.   Canadian Journal of Infectious Diseases & Medical Microbiology

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

(2015) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

(2015) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

(2015) Jasvinder A Singh et al.   LANCET

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

(2015) Robert E. Kalb et al.   JAMA Dermatology

Psoriasis Severity and the Prevalence of Major Medical Comorbidity

(2013) Howa Yeung et al.   JAMA Dermatology

Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study

(2012) M. Viguier et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety of treatment with biologics for psoriasis in daily practice: 5-year data

(2011) P.P.M. van Lümig et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre

(2008) R.B. Warren et al.   BRITISH JOURNAL OF DERMATOLOGY